Botulinum toxin type a and type b for sialorrhoea in Parkinson's disease: A case for switching therapy?

Journal of Rehabilitation Medicine

Volumn 40, Issue 10, 2008, Pages 882-883

  Santamato, Andrea ^a   Panza, Francesco ^a   Solfrizzi, Vincenzo ^b   Frisardi, Vincenza ^b   Ranieri, Maurizio ^b   Fiore, Pietro ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ABSENCE OF SIDE EFFECTS; AGED; ANTIBODY PRODUCTION; CASE REPORT; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; HYPERSALIVATION; LATENT PERIOD; LETTER; MALE; PARKINSON DISEASE; RATING SCALE; SCORING SYSTEM;

BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; HUMANS; NEUROMUSCULAR AGENTS; PARKINSON DISEASE; SIALORRHEA; TREATMENT OUTCOME;

EID: 56749096486     PISSN: 16501977     EISSN: None     Source Type: Journal    
DOI: 10.2340/16501977-0257     Document Type: Letter

References (17)

1. Intiso D, Basciani M, Di Rienzo F, Tolfa M, Grimaldi G, Fiore P. Botulinum toxin type A in the healing of ulcer following oromandibular dyskinesia in a patient in a vegetative state. J Rehabil Med 2008; 40: 315-316.
2. Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000; 54: 244-247.
3. Porta M, Gamba M, Bertacchi G, Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 2001; 704: 538-540.
4. Santamato A, Ianieri G, Ranieri M, Megna, M, Panza F, Fiore P, et al. Botulinum toxin type A in the treatment of sialorrhea in Parkinson's disease. J Am Geriatr Soc 2008; 56: 765-767.
5. Glogau RG. Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. Clin J Pain 2002; 18 Suppl 6: S191-S197.
6. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995; 45: 1743-1746.
7. Naumann M, Moore AP. Long-term safety of botulinum toxin type A. Mov Disord 2003; 18: 1080-1081.
8. Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993; 43: 1715-1718.
9. Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol 1991; 48: 1253-1256.
10. Brin MF. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl 1997; 6: S208- S220.
11. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53: 1439-1446.
12. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431-1438.
13. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993; 365: 160-163.
14. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359: 832-835.
15. Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 1988; 3: 73-78.
16. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62: 37-40.
17. Contarino MF, Pompili M, Tittoto P, Vanacore N, Sabatelli M, Cedrone A, et al. Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 299-303.